Diabetes insipidus medical therapy
|
Diabetes insipidus Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Diabetes insipidus medical therapy On the Web |
|
American Roentgen Ray Society Images of Diabetes insipidus medical therapy |
|
Risk calculators and risk factors for Diabetes insipidus medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The hallmark symptoms of both central and nephrogenic diabetes insipidus (DI) are polyuria, nocturia, and polydipsia due to the concentrating defect. Treatment of central DI is primarily aimed at decreasing the urine output, usually by increasing the activity of antidiuretic hormone (ADH, also called arginine vasopressin or AVP). However, nephrogenic diabetes insipidus (DI) results from resistance of the kidney to the actions of antidiuretic hormone(ADH). As a result, patients with this disorder are not likely to have a good response to hormone administration (as dDAVP) or to drugs that increase either the renal response to ADH or ADH secretion and so other treatment options must be explored.
Medical Therapy
Central Diabetes Insipidus
The mainstay of therapy for central diabetes insipidus is desmopressin. Fluid restriction should be observed. Dosing should be individualized to response.
- IV, SubQ: US labeling: 2 to 4 mcg daily (0.5 to 1 mL) in 2 divided doses or one-tenth (1/10) of the maintenance intranasal dose.
- IM, IV, SubQ: Canadian labeling (DDAVP Injection only): 1 to 4 mcg (0.25 to 1 mL) once daily or one-tenth (1/10) of the maintenance intranasal dose.
- Intranasal (100 mcg/mL nasal solution): Usual dose range: 10 to 40 mcg daily (0.1 to 0.4 mL) as a single dose or divided 2 to 3 times daily.
- Oral
- US labeling: Initial: 0.05 mg twice daily; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis (range: 0.1 to 1.2 mg divided 2 to 3 times daily).
- Canadian labeling: Initial: 0.1 mg 3 times daily; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis (maximum: 1.2 mg/day in 3 divided doses)
- Sublingual formulation
- [Canadian product]: DDAVP Melt: Initial: 60 mcg 3 times daily; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis. Usual maintenance: 120 to 720 mcg equally divided 2 or 3 times daily